(Q37593552)

21 August 2017

1 reference

title

Saquinavir, the pioneer antiretroviral protease inhibitor (English)

1 reference

21 August 2017

anti-retroviral agent

0 references

1 reference

Charles J L la Porte

1

1 reference

PubMed ID

19737048

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Drug Metabolism & Toxicology

21 August 2017

1 reference

21 August 2017

5

1 reference

21 August 2017

1313-1322

1 reference

21 August 2017

10

1 reference

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

A review of low-dose ritonavir in protease inhibitor combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Saquinavir exposure in HIV-infected patients with chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetics of saquinavir co-administered with cimetidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Interactions between protease inhibitors and acid-reducing agents: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Double-boosted protease inhibitor antiretroviral regimens: what role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 118

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Use of therapeutic drug monitoring in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Inhibitory quotient in HIV pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Dose reduction effective in alleviating symptoms of saquinavir toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Efficacy of Low-Dose Boosted Saquinavir Once Daily Plus Nucleoside Reverse Transcriptase Inhibitors in Pregnant HIV-1-Infected Women With a Therapeutic Drug Monitoring Strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

The Safety, Efficacy, and Pharmacokinetic Profile of a Switch in Antiretroviral Therapy to Saquinavir, Ritonavir, and Atazanavir Alone for 48 Weeks and a Switch in the Saquinavir Formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

Performance of Six Different Ritonavir-Boosted Protease Inhibitor–Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903273160

10.1517/17425250903273160

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19737048